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Summary
An 11-year-old boy developed severe syndrome of inappropriate antidiuretic hormone secretion (SIADH) after 
diagnosis of an intracranial B-cell lymphoma. His sodium levels dropped to 118–120 mmol/L despite 70% fluid 
restriction. For chemotherapy, he required hyperhydration, which posed a challenge because of severe hyponatraemia. 
Tolvaptan is an oral, highly selective arginine vasopressin V2-receptor antagonist, which has been licensed in adults 
for the management of SIADH and has been used in treating paediatric heart failure. Tolvaptan gradually increased 
sodium levels and allowed liberalisation of fluid intake and hyperhydration. Tolvaptan had profound effects on urinary 
output in our patient with increases up to 8 mL/kg/h and required close monitoring of fluid balance, frequent sodium 
measurements and adjustments to intake. After hyperhydration, tolvaptan was stopped, and the lymphoma went 
into remission with reversal of SIADH. We report one of the first uses of tolvaptan in a child with SIADH, and it was an 
effective and safe treatment to manage severe SIADH when fluid restriction was not possible or effective. However, 
meticulous monitoring of fluid balance and sodium levels and adjustments of fluid intake are required to prevent rapid 
sodium changes.
Learning points:
•	 Tolvaptan can be used in paediatric patients with SIADH to allow hyperhydration during chemotherapy.
•	 Tolvaptan has profound effects on urinary output and meticulous monitoring of fluid balance and sodium  
levels is therefore warranted.
•	 Tolvaptan was well tolerated without significant side effects.
Background
The syndrome of inappropriate antidiuretic hormone 
secretion (SIADH) is a common cause of hyponatraemia 
in paediatrics (1). The aetiology is variable and includes 
increased cranial ADH production (infections, thrombosis, 
haemorrhage, cerebral malignancies and other cerebral 
diseases), drugs, pulmonary disease and ectopic 
production of ADH (malignancies) (1). The first-line 
treatment consists of fluid restriction in asymptomatic 
children. More severe forms with neurological symptoms 
may require administration of hyperosmolar saline, 
which is often combined with furosemide. In most cases, 
the SIADH is temporary and resolves by treating the 
underlying cause.
In the past decade, an alternative treatment option 
for SIADH has become available – the vaptans (2). 
Vaptans are vasopressin receptor antagonists. There are 
three types of vasopressin receptors: V1a, V1b and V2. 
Binding of AVP to the V2 receptor in the renal collecting 
duct leads to insertion of aquaporin 2 water channels in 
the apical membrane promoting re-absorption of water. 
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Vaptans compete with AVP at the receptor-binding site, 
thus promoting the excretion of free water (3). Tolvaptan 
is a selective V2 receptor antagonist and is the only 
vaptan approved by the European Medicines Agency. 
Data regarding the safety and efficacy of vaptan use in 
paediatrics are limited, and the use of tolvaptan in SIADH 
in childhood has not previously been reported until 
recently in infants (4).
We present a case of a child with an intracranial 
lymphoma and severe SIADH, refractory to treatment 
with fluid restriction. Although the hyponatraemia 
was not accompanied by any neurological symptoms, a 
challenging situation arose as the chemotherapy required 
hyperhydration. Tolvaptan allowed the liberalisation of 
his fluid intake and eventually hyperhydration during the 
first course of chemotherapy.
Case presentation
An 11-year-old otherwise healthy boy presented to 
the Emergency Department with a 2-week history of 
headaches, morning sickness and a collapse on the day of 
presentation. A CT scan showed a multifocal intracranial 
tumour with mild hydrocephalus, which was confirmed 
by MRI (Fig.  1). He was started on dexamethasone and 
admitted, awaiting further diagnostic tests. In the 
first week of his admission, he developed SIADH in 
keeping with the diagnostic criteria of Spasovski et  al. 
(5): (day 6: plasma sodium 126 mmol/L (ref. 135–145), 
plasma osmolality 263 mOsm/kg (ref. 280–300), urine 
osmolality 195 mOsm/kg, urine sodium 36.6 mmol/L 
and plasma creatinine 39 μmol/L (ref. 35–80)), which was 
unresponsive to 70% fluid restriction (day 12: plasma 
sodium 119 mmol/L, plasma osmolality 245 mOsm/kg, 
urine osmolality 645 mOsm/kg, urine sodium 209 mmol/L, 
plasma creatinine 32 μmol/L, plasma urea 5.0 mmol/L 
(ref. 2.9–6.4) and uric acid 107 nmol/L (ref. 140–320)). 
The possibility of cerebral salt wasting was considered, 
but the clinical picture was more in keeping with SIADH, 
with no signs of dehydration, increase in weight and low 
urine output.
Investigation
A biopsy on day 5 revealed that the tumour was a B-cell 
lymphoma. An MRI of spine and CT of thorax–abdomen–
pelvis showed no metastases or lymphadenopathy, 
but some free fluid in the pelvis and left iliac fossa, of 
uncertain clinical significance. In view of a borderline low 
free T4 (FT4 11.2 pmol/L (ref. 10–19.9), TSH 0.19 U/L (ref. 
0.35–5.3)) and the appearances of an intracranial tumour, 
the patient was commenced on levothyroxine on day 6.
Treatment
Treatment for the B-cell lymphoma followed FAB 
LMB 96 (6). Initial treatment involved the use of 
hyperhydration to prevent tumour lysis syndrome and 
to deliver high-dose methotrexate (MTX), which posed 
a challenging situation in view of his concurrent SIADH 
and severe hyponatraemia, despite 70% fluid restriction 
(consistent with allowing an intake equivalent to 30% 
maintenance fluids). Tolvaptan was started on day 13 
at a dose of 0.14 mg/kg once a day and titrated up to 
0.28 mg/kg twice a day based on fluid requirements 
and serum sodium levels. The tablets were dispersed 
in water and the dose taken as an aliquot. Tolvaptan 
gradually increased the sodium levels and allowed 
liberalisation of fluid intake and hyperhydration up 
to 3.8 times the normal fluid maintenance (Fig. 2). Of 
note, the administration of tolvaptan in our patient had 
profound effects on urinary output with increases up to 
8 mL/kg/h and required close monitoring in an intensive 
care setting with frequent sodium measurements 
and adjustments to intake. The boy also developed a 
desquamative rash on the dorsal side of both hands. 
Figure 1
MRI scan showing a multifocal intracranial mass, with lesions in the 
anterior part of the corpus callosum, extending inferiorly on the septum 
pellucidum and columns of the fornices, adjacent foci of subependymal 
enhancing tumour in the heads of the caudate nuclei and anterior part 
of the left thalamus, tumour in the pineal region, inferior third ventricle 
and roof of the fourth ventricle.
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As the rash appeared whilst he was also receiving 
chemotherapy, it was unclear whether this was related 
to tolvaptan. After hyperhydration and clearance of 
methotrexate, tolvaptan doses and frequency could be 
decreased and eventually stopped allowing a normal 
fluid intake and acceptable sodium levels.
Outcome and follow-up
After this first course of chemotherapy, the SIADH 
subsided and subsequent courses could be administered 
without any problems. The tumour went into remission, 
and there has been no recurrence of the tumour after 
almost 2 years of follow-up. The child has entered into 
spontaneous puberty. Follow-up endocrine testing 
showed a normal cortisol response but insufficient 
growth hormone (GH) response on two occasions, and 
he will be started on GH in due course.
Discussion
The exact aetiology of SIADH in our case remains 
unknown, but various mechanisms could be considered, 
such as ADH production from lymphoma cells or 
intracranial effects of the tumour. The use of tolvaptan in 
this child with severe SIADH allowed liberalisation of fluid 
intake and eventually hyperhydration after high dose 
MTX. Current treatment options for SIADH are limited 
and often not effective. In most cases of asymptomatic 
hyponatraemia as a consequence of SIADH, treatment 
can be limited to fluid restriction. However, as our case 
demonstrates, fluid restriction is not always feasible.
Another drug which has previously been used in 
patients with hyponatraemia is the tetracycline derivative 
antibiotic demeclocycline. Although the mode of action is 
not well understood, it can induce nephrogenic diabetes 
insipidus, and a recent systematic review reported that 
demeclocycline was able to increase sodium levels in 
about 60% of patients with hyponatraemia secondary to 
SIADH (7). However, the onset of action is unpredictable 
and varies between 2 and 5 days (7). The effect is 
considered to be milder than that of the vaptans, and it 
is questionable whether this would have enabled us to 
hyperhydrate our patient.
Reports regarding the use of vaptans in paediatrics 
are scarce. Tolvaptan has been reported in a case series 
of 28 paediatric patients with heart failure (8), a patient 
with restrictive cardiomyopathy (9) and a patient with 
massive oedema due to nephrotic syndrome (10). In these 
paediatric case reports and case series, tolvaptan was well 
tolerated and considered to be a safe treatment. There has 
been a recent report of the use of tolvaptan for SIADH 
in infancy (4), but experience is scarce. An intravenous 
form of vaptan, conivaptan, has previously been used in 
the management of hyperhydration during SIADH (11). 
Conivaptan is however not licensed in Europe.
Both demeclocycline and vaptans could potentially 
cause harm, such as the osmotic demyelination syndrome 
when the sodium increases too rapidly. A recent 
clinical practice guideline, developed as a joint venture 
of the European Society of Intensive Care Medicine, 
European Society for Endocrinology and European Renal 
Association-European Dialysis and Transplant Association, 
recommended against using these agents in patients with 
asymptomatic hyponatraemia as a consequence of SIADH 
(5). As illustrated by our case, there may however be 
situations where fluid restriction is not possible.
The administration of tolvaptan in our patient 
had profound effects on urinary output, and required 
close monitoring of sodium and fluid balance, and 
adjustments to the intake in an intensive care setting. 
Of note, Tzoulis et  al. described their experiences with 
tolvaptan in a case series of adult patients (mean age 74.4 
years) and highlighted the risk of overly rapid sodium 
correction, which seemed to be greater in patients with 
lower starting sodium levels (12). Too rapid correction 
of hyponatraemia may lead to osmotic demyelination 
syndrome. We therefore recommend that tolvaptan 
should be started at a low dose, and then should be 
slowly increased according to response, and this should 
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Figure 2
Sodium, weight, tolvaptan doses, urine output (mL/kg/h) and fluid intake 
as a percentage of normal maintenance vs time. The right y-axis is used 
for both urine output and fluid intake where ‘2’ resembles a urine output 
of 2 mL/kg/h or 200% of normal fluid maintenance respectively. Each grey 
diamond indicates a dose of tolvaptan and the dose in mg can be read 
from the right off-set y-axis.
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be accompanied by frequent monitoring of sodium levels 
and urinary output.
In conclusion, tolvaptan is a safe treatment in 
situations of childhood SIADH where fluid restriction 
is not possible and hyperhydration is required, but 
meticulous monitoring of sodium levels and adjustment 
of fluid intake are warranted.
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